INCY 241220 75.00P (INCY241220P75000) Stock Options, News & Quotes

US OptionsDetailed Quotes

INCY241220P75000

Watchlist

7.90
+4.30+119.44%

15min DelayClose Nov 19 15:59 ET

11.00High7.60Low

Intraday

5D
Daily

News

Top Gap Ups and Downs on Tuesday: WMT, INTU, SMFG and More
Moomoo News23minutes ago · Markets
Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
MT Newswires17:06 ET
Bitcoin Climbs to Fresh High, Market Shifts into Climb | Wall Street Today
Kevin Travers16:25 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga16:05 ET
Top Midday Decliners
MT Newswires14:45 ET
Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
MT Newswires14:18 ET

Comments

韭菜变主力

4 hours ago

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

The Thinker

Oct 29 19:14

Tech Stocks Surge While Dow Falters as U.S. Markets Prepare for Key Data

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

Trytosaveabit

Aug 14 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)